*Disclaimer

CYNATA THERAPEUTICS LIMITED (ASX: CYP)

🔗 📄 📈

CYP: Ethics Committee Approval for Proposed aGvHD Phase 2 Trial

CYNATA THERAPEUTICS LIMITED

2023-04-12 09:37:00

CYP: Cynata completes $5.0m Placement and launches SPP

CYNATA THERAPEUTICS LIMITED

2023-04-06 09:24:00

CYP: Cynata Adds New Sites for DFU Clinical Trial

CYNATA THERAPEUTICS LIMITED

2023-03-16 13:25:00

CYP: Cynata Receives IRB Approval for aGvHD Clinical Trial

CYNATA THERAPEUTICS LIMITED

2023-01-30 09:06:00

CYP: Notice Of Acceptance For Cynata Australian Patent

CYNATA THERAPEUTICS LIMITED

  1. Cynata Therapeutics Limited has received a Notice of Acceptance from IP Australia for a patent application covering its proprietary Cymerus ™ mesenchymal stem cell (MSC) platform technology.
  2. The patent application entitled “Method for Treating Allergic Airways Disease (AAD)/Asthma” is wholly owned by Cynata and describes a novel method of use of Cynata’s proprietary Cymerus MSC products in treating diseases of the lungs and airways.
  3. The patent adds to the existing broad and comprehensive IP protection of the Cymerus platform and its unique ability to yield highly consistent MSC s at scale, from a single donation, to create therapeutic stem cell products.

2023-01-09 12:41:00